Schroder Investment Management Group decreased its holdings in Syneos Health Inc (NASDAQ:SYNH) by 22.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 456,005 shares of the company’s stock after selling 130,103 shares during the quarter. Schroder Investment Management Group’s holdings in Syneos Health were worth $21,387,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. PNC Financial Services Group Inc. bought a new position in Syneos Health in the 1st quarter valued at $111,000. Group One Trading L.P. bought a new position in Syneos Health in the 1st quarter valued at $118,000. Envestnet Asset Management Inc. bought a new position in Syneos Health in the 1st quarter valued at $124,000. CIBC World Markets Inc. bought a new position in Syneos Health in the 1st quarter valued at $231,000. Finally, LPL Financial LLC bought a new position in Syneos Health in the 1st quarter valued at $236,000.
SYNH stock opened at $44.82 on Friday. The firm has a market cap of $5.30 billion, a PE ratio of 23.10, a PEG ratio of 1.22 and a beta of 0.81. Syneos Health Inc has a twelve month low of $31.10 and a twelve month high of $59.45. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 1.01.
In other news, major shareholder H. Lee Equity Fund Vi Thomas sold 6,000,000 shares of the business’s stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $49.73, for a total transaction of $298,380,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.57% of the company’s stock.
SYNH has been the subject of a number of recent research reports. ValuEngine downgraded Syneos Health from a “hold” rating to a “sell” rating in a research report on Thursday, September 6th. KeyCorp boosted their target price on Syneos Health from $54.00 to $59.00 and gave the stock an “overweight” rating in a research report on Friday, August 10th. Mizuho restated a “hold” rating and set a $51.00 target price on shares of Syneos Health in a research report on Monday, August 6th. Barclays restated a “hold” rating and set a $51.00 target price (up previously from $43.00) on shares of Syneos Health in a research report on Friday, August 3rd. Finally, Evercore ISI initiated coverage on Syneos Health in a research report on Thursday, October 4th. They set an “outperform” rating and a $58.00 target price for the company. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $53.91.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Featured Article: What is the yield curve?
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.